ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2239

Prevalence of Gout and Hyperuricemia and Association with Fat Mass and Fat Free Mass: Results from a Population-Based Study

Tiffany K. Gill1, Kimberley Ting2, Graeme R Tucker1, E. Michael Shanahan3,4 and Catherine Hill5,6, 1Medicine, The University of Adelaide, Adelaide, Australia, 2Rheumatology, The Queen Elizabeth Hospital, Adelaide, Australia, 3Flinders University, Adelaide, Australia, 4Repat General Hospital, Flinders University, Adelaide, Australia, 5The Health Observatory, The University of Adelaide, Adelaide, Australia, 6Rheumatology Unit, The Queen Elizabeth Hospital, Woodville, Australia

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Dual energy x-ray absorptiometry (DEXA), gout, hyperuricemia and population studies

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 10, 2015

Title: Epidemiology and Public Health Poster III (ACR): Gout and Non-Inflammatory Musculoskeletal Conditions

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Gout and hyperuricemia are major co-morbid health issues worldwide, with a known association with metabolic syndrome.  Only one previous study based in Vietnam, has investigated the association between body composition and gout1. The aim of this study was to determine the prevalence of self-reported medically diagnosed gout and laboratory determined hyperuricemia and to examine whether fat mass and free fat mass were predictors of gout in a population-based cohort.

Methods: The North West Adelaide Health Study (NWAHS) is a longitudinal cohort study with three stages of data collection. Each stage comprised a self-complete questionnaire, clinic assessment and Computer Assisted Telephone Interview (CATI).  In Stage 2 (2004-06), Dual Energy X-ray Absorptiometry (DXA) scans were undertaken on those aged 50 years and over. Additional data included demographics and body mass index (BMI). In Stage 3 (2008-10) participants were asked if a doctor had ever diagnosed them with gout, and a serum uric acid (SUA) measurement was obtained. Participants were defined as having gout if they had self-reported medically diagnosed gout or were taking any gout specific medication (allopurinol, colchicine, probenecid). Hyperuricemia was defined as a SUA >=0.45mmol/l. The association between reporting gout or hyperuricemia in Stage 3 and the measurements of BMI, fat mass, fat mass index, fat free mass and fat free mass index were all examined, using logistic regression analysis.

Results: The prevalence of gout was 9.6% (15.2% and 5.2%, p<0.001 for males and females respectively) and hyperuricemia was 6.8% (males vs females, 11.0% vs 3.5%, p<0.001).  The presence of both gout and hyperuricemia was not independently associated with fat mass index but was associated with all other measures.  The association with higher BMI and fat free mass index remained after adjustment for age and sex for gout, and the association with fat mass and fat mass index became significant. The association with fat free mass remained significant for hyperuricemia even after adjustment of age and sex.  When adjusted for body composition, fat mass and fat mass index were significantly associated with gout (Table 1).

Conclusion:

This is the first study of body composition and gout in a Western population. The prevalence of gout and hyperuricemia is high. BMI and body composition measurements have been shown to be predictors of gout and hyperuricemia in a community sample and may need to be considered when treating these conditions. 

1 Dao HH, Harun-Or-Rashid M, Sakamoto J. Body composition and metabolic syndrome in patients with primary gout in Vietnam. Rheumatology. 2010;49:2400-7.

Table 1: Unadjusted and adjusted association between gout and hyperuricemia and BMI and body composition

 

BMI

Fat massa

Fat mass indexa

Fat free massb

Fat free mass indexb

Unadjusted

OR (95% CI)

  p-value

OR (95% CI)

  p-value

OR (95% CI)

  p-value

OR (95% CI)

  p-value

OR (95% CI)

  p-value

No gout

1.00

1.00

1.00

1.00

1.00

Gout

1.08 (1.03-1.13)

0.001

1.02 (0.99-1.04)

0.130

1.03 (0.97-1.09)

0.339

1.04 (1.02-1.06)

<0.001

1.26 (1.15-1.39)

<0.001

Adjusted for   age and sex

 

 

 

 

 

No gout

1.00

1.00

1.00

1.00

1.00

Gout

1.11 (1.06-1.17)

<0.001

1.05 (1.02-1.08)

<0.001

1.16 (1.07-1.24)

<0.001

1.03 (0.99-1.07)

0.10

1.24 (1.08-1.41)

0.002

Adjusted for   age, sex and body composition

 

 

 

 

 

No gout

 

1.00

1.00

1.00

1.00

Gout

 

1.05 (1.02-1.08)

0.002

1.12 (1.04-1.22)

0.006

1.00 (0.96-1.05)

0.93

1.12 (0.96-1.30)

0.160

 

 

 

 

 

 

 

BMI

Fat massa

Fat mass indexa

Fat free massb

Fat free mass indexb

Unadjusted

OR (95% CI)

  p-value

OR (95% CI)

  p-value

OR (95% CI)

  p-value

OR (95% CI)

  p-value

OR (95% CI)

  p-value

No hyperuricemia

1.00

1.00

1.00

1.00

1.00

Hyperuricemia

1.08 (1.02-1.14)

0.008

1.02 (0.99-1.05)

0.13

1.02 (0.95-1.09)

0.63

1.05 (1.03-1.08)

<0.001

1.28 (1.15-1.43)

<0.001

Adjusted for   age and sex

 

 

 

 

 

No hyperuricemia

1.00

1.00

1.00

1.00

1.00

Hyperuricemia

1.11 (1.04-1.18)

0.001

1.05 (1.02-1.08)

0.002

1.13 (1.04-1.23)

0.004

1.06 (1.02-1.11)

0.009

1.24 (1.06-1.44)

0.008

Adjusted for   age, sex and body composition

 

 

 

 

 

No hyperuricemia

 

1.00

1.00

1.00

1.00

Hyperuricemia

 

1.04 (1.00-1.07)

0.030

1.09 (1.00-1.20)

0.063

1.04 (0.99-1.09)

0.144

1.15 (0.96-1.36)

0.130

aModels with fat mass and fat mass index adjusted for fat free mass and fat free mass index respectively

bModels with fat free mass and fat free mass index adjusted for fat mass and fat mass index respectively


Disclosure: T. K. Gill, None; K. Ting, None; G. R. Tucker, None; E. M. Shanahan, None; C. Hill, None.

To cite this abstract in AMA style:

Gill TK, Ting K, Tucker GR, Shanahan EM, Hill C. Prevalence of Gout and Hyperuricemia and Association with Fat Mass and Fat Free Mass: Results from a Population-Based Study [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/prevalence-of-gout-and-hyperuricemia-and-association-with-fat-mass-and-fat-free-mass-results-from-a-population-based-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prevalence-of-gout-and-hyperuricemia-and-association-with-fat-mass-and-fat-free-mass-results-from-a-population-based-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology